Ratings Dermapharm Holding SE

Equities

DMP

DE000A2GS5D8

Real-time Estimate Tradegate Other stock markets 01:00:25 02/05/2024 pm IST			5-day change	1st Jan Change
31.5 ^EUR	+0.32%		-3.08%	-25.60%

04/04	DERMAPHARM : Berenberg keeps its Buy rating	ZD
28/03	Dermapharm Holding SE Reports Earnings Results for the Full Year Ended December 31, 2023	CI

Summary

From a short-term investment perspective, the company presents a deteriorated fundamental configuration.

Strengths

Before interest, taxes, depreciation and amortization, the company's margins are particularly high.
Given the positive cash flows generated by its business, the company's valuation level is an asset.
Sales forecast by analysts have been recently revised upwards.
Analysts have a positive opinion on this stock. Average consensus recommends overweighting or purchasing the stock.
The difference between current prices and the average target price is rather important and implies a significant appreciation potential for the stock.
Over the past twelve months, analysts' opinions have been strongly revised upwards.

Weaknesses

According to forecast, a sluggish sales growth is expected for the next fiscal years.
The group shows a rather high level of debt in proportion to its EBITDA.
For the last four months, earnings estimated by analysts have been revised downwards with respect to the next two years.
The price targets of analysts who cover the stock differ significantly. This implies difficulties in evaluating the company and its business.
The group usually releases earnings worse than estimated.

Ratings chart - Surperformance

Chart ESG Refinitiv

Sector: Pharmaceuticals

	1st Jan change	Capi.	ESG Refinitiv
DERMAPHARM HOLDING SE	-25.60%	1.81B	B-
ELI LILLY AND COMPANY	+33.25%	699B	C+
NOVO NORDISK A/S	+25.03%	571B	B
JOHNSON & JOHNSON	-3.55%	364B	C+
MERCK & CO., INC.	+18.16%	326B	B-
ABBVIE INC.	+4.36%	286B	C+
ASTRAZENECA PLC	+14.85%	236B	B+
NOVARTIS AG	+5.27%	198B	B-
ROCHE HOLDING AG	-9.57%	194B	A+
AMGEN INC.	-3.69%	149B	C+

Investor Rating

Trading Rating

ESG Refinitiv

Financials

Sales growth

Earnings Growth

EBITDA / Sales

Profitability

Finances

Valuation

P/E ratio

EV / Sales

Price to Book

Price to Free Cash Flow

Yield

Momentum

1 year Revenue revision

4 months Revenue revision

7 days Revenue revision

1 year EPS revision

4 months EPS revision

Consensus

Analyst Opinion

Potential Price Target

4m Target Price Revision

4m Revision of opinion

12m Revision of opinion

Business Predictability

Analyst Coverage

Divergence of Estimates

Divergence of analysts' opinions

Divergence of Target Price

Earnings quality

Environment

Emissions

Innovation

Use of resources

Governance

CSR Strategy

Management

Shareholders

Controversy

Technical analysis

ST Timing

MT Timing

LT Timing

RSI

Bollinger Spread

Unusual volumes